Sample Page

1Bz-LSD, also known as 1-benzoyl-LSD or as SYN-L-018, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is thought to be a prodrug of LSD.[1][2] The drug was patented by Lizard Labs in 2024.[2] Subsequently, it was encountered online as a novel designer drug in July 2024.[1] 1Bz-LSD has been sold in the form of blotter tabs and microdots containing 10 μg and 200 μg doses per unit.[1] 1Bz-LSD is not an explicitly controlled substance in the United States[3] or in Canada.[4]

See also

References

  1. ^ a b c d e “1Bz-LSD”. AIPSIN (in Russian). Retrieved 1 January 2026.
  2. ^ a b c WO 2024/028495, Stratford A, Williamson JP, ”Prodrugs of Substituted Ergolines”, published 8 February 2024, assigned to Synex Holdings BV 
  3. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  4. ^ “Controlled Drugs and Substances Act”. Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.